Author:
Trickey Adam,Bivegete Sandra,Duffell Erika,McNaughton Anna L.,Nerlander Lina,Walker Josephine G.,Fraser Hannah,Hickman Matthew,Vickerman Peter,Brooks-Pollock Ellen,Christensen Hannah
Abstract
AbstractBackgroundHepatitis B virus (HBV) epidemiology in Europe differs by region and population risk group, and data are often incomplete. We estimated chronic HBV prevalence as measured by surface antigen (HBsAg) among general and key population groups for each country in the European Union, European Economic Area and the United Kingdom (EU/EEA/UK), including where data are currently unavailable.MethodsWe combined data from a 2018 systematic review (updated in 2021), data gathered directly by the European Centre for Disease Control (ECDC) from EU/EEA countries and the UK and further country-level data. We included data on adults from the general population, pregnant women, first time blood donors (FTBD), men who have sex with men (MSM), prisoners, people who inject drugs (PWID), and migrants from 2001 to 2021, with three exceptions made for pre-2001 estimates. Finite Mixture Models (FMM) and Beta regression were used to predict country and population group HBsAg prevalence. A separate multiplier method was used to estimate HBsAg prevalence among the migrant populations within each country, due to biases in the data available.ResultsThere were 595 included studies from 31 countries (N = 41,955,969 people): 66 were among the general population (mean prevalence ($$\stackrel{-}{p}$$) 1.3% [range: 0.0-7.6%]), 52 among pregnant women ($$\stackrel{-}{p}=$$1.1% [0.1–5.3%]), 315 among FTBD ($$\stackrel{-}{p}=$$0.3% [0.0-6.2%]), 20 among MSM ($$\stackrel{-}{p}=$$1.7% [0.0-11.2%]), 34 among PWID ($$\stackrel{-}{p}=$$3.9% [0.0-16.9%]), 24 among prisoners ($$\stackrel{-}{p}=$$2.9% [0.0-10.7%]), and 84 among migrants ($$\stackrel{-}{p}=$$7.0% [0.2–37.3%]). The FMM grouped countries into 3 classes. We estimated HBsAg prevalence among the general population to be < 1% in 24/31 countries, although it was higher in 7 Eastern/Southern European countries. HBsAg prevalence among each population group was higher in most Eastern/Southern European than Western/Northern European countries, whilst prevalence among PWID and prisoners was estimated at > 1% for most countries. Portugal had the highest estimated prevalence of HBsAg among migrants (5.0%), with the other highest prevalences mostly seen in Southern Europe.ConclusionsWe estimated HBV prevalence for each population group within each EU/EAA country and the UK, with general population HBV prevalence to be < 1% in most countries. Further evidence is required on the HBsAg prevalence of high-risk populations for future evidence synthesis.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. World Health Organization. Hepatitis B Fact sheet. Geneva, Switzerland: World Health Organization; 2022.
2. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 2016.
3. European Centre for Disease Prevention and Control. Monitoring of responses to the hepatitis B and C epidemics in EU/EEA countries – 2020 data. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2022.
4. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, et al. A comparison of hepatitis B seroepidemiology in ten european countries. Epidemiol Infect. 2009;137(7):961–9.
5. Mason LMK, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Eurosurveillance. 2019;24(30):5–20.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献